Skip to main content

About

News

Careers

Help

Login

Choose Language

Advanced Modalities

Labcorp provides tailored testing solutions and global laboratory capabilities from next-generation biologics to cell and gene therapies, antibody-drug conjugates, and more.
Start a Conversation

Your lab partner in end-to-end testing strategies for advanced therapeutic modalities

To meet strict regulatory and clinical standards, biologics and precision medicines must be tested thoroughly throughout development stages to characterize critical features like product identity, potency, stability and immunogenicity. Applying advanced analytical methods and comprehensive safety protocols minimizes risks and setbacks, while ongoing quality monitoring and data-driven decisions help developers adapt to new science and regulations. This means therapies can reach patients with safety and performance. Labcorp provides end-to-end testing solutions for advanced therapeutics, supporting every development phase from discovery to regulatory submission and beyond. Whether you're advancing a blockbuster oncology therapy or a novel cell or gene therapy, Labcorp can support your clinical trial.

Antibody-drug conjugates (ADCs)

Spanning bioanalysis, immunogenicity and companion diagnostic development, our ADC experience supports every step of your development journey. We help biopharma partners optimize payload delivery and patient targeting strategies with precision biomarker support.

Illustration of antibody drug conjugates. Antibody drug conjugates can consist of a monoclonal antibody (blue/purple) and a cytotoxic payload (orange) for targeting and destroying specific cells in the body
Illustration of antibody drug conjugates. Antibody drug conjugates can consist of a monoclonal antibody (blue/purple) and a cytotoxic payload (orange) for targeting and destroying specific cells in the body

Cell therapy

Having supported the development of all seven FDA-approved CAR T-cell therapies, we support your adoptive cell therapies with a reliable depth of experience. Benefit from end-to-end lab services for adoptive cell therapies, including tumor-infiltrating lymphocytes, CAR NK cells and gene-modified T-cells with technologies like single-cell sequencing, mass cytometry and spatial profiling enabling deep cellular insights.

Gene therapy

From viral vector characterization to gene editing validation of CRISPR-based therapies, our labs have supported a range of novel modalities including more than 80% of FDA-approved gene replacement therapies. Whether you need GMP-compliant testing, regulatory guidance or global logistics support, we help you reach IND/CTA milestones and scale efficiently.

Illustration of antibody drug conjugates. Antibody drug conjugates can consist of a monoclonal antibody (blue/purple) and a cytotoxic payload (orange) for targeting and destroying specific cells in the body

How does Labcorp help you to meet the complex requirements of advanced modalities in clinical development?

Central laboratory services for safety, quality and support

Unified by standardized processes, procedures, and instrumentation, our global network of central, bioanalytical, CMC, and specialty laboratories delivers high-quality science and data tailored to advanced modalities. Leverage our integrated advisory services for logistics and biomarker strategy to enable a comprehensive and modality-specific approach to clinical trial testing.

Learn more

Your partner for progressing your advanced therapy

Gain support designing and executing clinical trial programs with precision and confidence with our highly scientific approach, combined with deep modality-specific expertise and global lab infrastructure. From biomarker strategy to operational execution, we’re here to support your journey from discovery to patient impact. Let’s advance your next breakthrough—together.

You might also be interested in

One partner for your advanced therapy development